Saturday, October 31, 2026

Talent Analytics Startup Chooses Portugal to Enter EU Market

Cristina Costa

January 8, 2020

Shivam Dhawan is the founder of Getboarded, an Artificial Intelligence and Big Data recruiting service platform in which bots are trained to help university applicants better match their soft skills with open vacancies. Photo credit: Via News.

As the crowds were rushing away from Web Summit 2019 to Lisbon Airport, we used the calmer surroundings to talk at Startup Portugal's double-decker with Shivam Dhawan, founder at Getboarded.

Getboarded is an artificial intelligence and big data recruiting service platform, in which bots are trained to help university applicants better match their soft skills with open vacancies.

Shivam Dhawan, a web analytics expert educated in India, is an young entrepreneur who brought his project to Lisbon to enter the European market. He's using “Startup Visa” program launched by the former Minister João Vasconcelos at the 2017 edition of Web Summit.

https://www.youtube.com/watch?v=Wz7VWk4eGfk

Getboarded is part of a business incubation program linked to the University of Aveiro headed by Adriana Costa, executive director at the Science & Innovation Park (PCI) in Aveiro.

Half an hour's drive away from Portugal’s Northern metropolitan area of Porto, Aveiro is mostly known abroad as the Venice of Portugal for its natural beauty deriving from its lagoon and river channel system.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com